Skip to content
Oligon Logo

Breaking through
complex diseases

We translate genomic intelligence
into multitargeting therapies

Multimodal RNA drugs to reverse resistance and improve clinical outcomes

Multimodal

We combine the potent binding of high performance aptamer binders with the flexible silencing power of RNAi

Multitargeted

SeekRs™ have the unique ability to target 4 or more pathways with a single agent

Multifunctional

SeekRs™ can be directed to any cell type and can be designed to influence a wide spectrum of cellular funtions and clinical phenotypes
SeekRTM Platform

Transformative
RNA therapeutics
platform

siRNA, RNA therapeutics, oncology, immunotherapy, ADC, IO, cancer, research, pharmaceutical, biotechnology, RNAi, aptamer, multi-targeting, gene therapy, SeekR, Oligon, complex disease, patient outcomes, technology platform 
SeekRTM Platform

Pipeline of paradigm
shifting RNA therapies
across multiple indications

OligonTM is pioneering a new class of multimodal and multitargeting RNA therapies to transform outcomes for complex diseases

Leadership

Our Executive Leadership Team

Spyro Mousses, PhD Founder, Chief Executive Officer and Chairman of the Board

Spyro Mousses, PhD

Founder, Chief Executive Officer and Chairman of the Board

James Silver, LLM Chief Operating Officer

James Silver, LLM

Chief Operating Officer

Andrew Matricaria, MBA Chief Financial Officer

Andrew Matricaria, MBA

Chief Financial Officer

Culture & Careers

A culture of innovation

We aim to change the clinical status quo by pioneering a new approach to treating complex diseases. Disrupting industries takes tremendous grit, commitment, and courage so we believe in a culture that seeks excellence.